Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors

Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More